Clinical trials aimed at increasing airway S-nitrosothiols, by inhibiting S-nitrosoglutathione reductase (GSNOR), are underway to enhance surface expression of cystic fibrosis transmembrane conductance regulator as treatment for cystic fibrosis. Here, CFTR is linked to cystic fibrosis.